Skip to main content
Journal of Epidemiology logoLink to Journal of Epidemiology
. 2019 May 5;29(5):197–204. doi: 10.2188/jea.JE20180007

Cholangiocarcinoma Trends, Incidence, and Relative Survival in Khon Kaen, Thailand From 1989 Through 2013: A Population-Based Cancer Registry Study

Supot Kamsa-ard 1,2, Vor Luvira 2,3, Krittika Suwanrungruang 2,4, Siriporn Kamsa-ard 1,2, Varisara Luvira 5, Chalongpon Santong 4, Tharatip Srisuk 3, Ake Pugkhem 3, Vajarabhongsa Bhudhisawasdi 3, Chawalit Pairojkul 6
PMCID: PMC6445798  PMID: 30078813

Abstract

Background

Cholangiocarcinoma (CCA) is a common malignancy in northeastern Thailand. Over the last 4 decades, several policies have been implemented for its prevention, but there has been no update on the trends and relative survival (RS). Our aim was (a) to perform a statistical assessment of the incidence trends of CCA and project future trends, and (b) to estimate relative survival.

Methods

All cases of CCA diagnosed from 1989 through 2013 were abstracted from the Khon Kaen Cancer Registry (KKCR). A jointpoint regression model was used to estimate the annual percentage change (APC) and to project future trends. We also calculated RS.

Results

There were 11,711 cases of CCA. The incidence rate increased with an APC of 1.79% (95% confidence interval [CI], −0.2 to 3.8) from 1989 through 2002, and decreased with an APC of −6.09% (95% CI, −8.2 to −3.9) from 2002 through 2013. The projected incidence of CCA should stable over the next 10 years, albeit higher than the world rate. The respective 5-year RS for both sexes for age groups of 30–40, 41–45, 51–60, and 61–98 years was 22.3% (95% CI, 16.8–29.5), 14.3% (95% CI, 12.0–17.0), 8.6% (95% CI, 7.8–10.0), and 7.2% (95% CI, 6.4–8.0).

Conclusion

The incidence rate of CCA has decreased since 2002, representing a real decline in the risk of CCA. The incidence of CCA is projected to stabilize by 2025. The survival of patients with CCA remains poor.

Key words: cholangiocarcinoma, trend, incidence, relative survival, cancer registry

INTRODUCTION

Cholangiocarcinoma (CCA) is a major cause of cancer mortality around the world.1 In Thailand, from 1988 through 2012, the respective age-standardized rate (ASR) of liver and bile duct cancer was between 53.4 and 94.8 per 100,000 for males and 18.5 and 39.4 per 100,000 for females. Among affected persons, CCA was the most common cell type, comprising between 82.0% and 89.0% of all detected primary liver cancers.29

Several risk factors for CCA have been investigated in Thailand, but Opisthorchis viverrini is most often implicated in the genesis of CCA.1013 Since 1987, as a means of limiting the incidence of CCA, a number of government policies have been implemented to eradicate O. viverrini infection.14 Treatment of CCA has also been improved through (a) better and more timely use of diagnostic technology, (b) refined surgical techniques, and (c) increasing the number of surgeons. We reported the declining trend in the incidence of CCA over the past 20 years, and hypothesized this trend represents a real reduced risk for CCA.15 We attempted to use our reported data to simulate the predicted incidence of CCA in the future, but the reported incidence was not sufficiently stable. Therefore, we extended the period studied in order to (a) perform a statistical assessment of the incidence trends of CCA, (b) project future trends in the incidence of CCA, (c) evaluate the effectiveness of the control policies, and (d) evaluate whether the various treatment protocols have improved survival.

MATERIAL AND METHODS

Data for the study were from the Khon Kaen Cancer Registry (KKCR), a population-based cancer registry for Khon Kaen Province in northeastern Thailand. The KKCR began in 1985. According to estimates from the census data of the National Statistical Office for 201216 (available at URL: http://www.nso.go.th/), the KKCR contains data on 1.7 million patients comprising all cancer sites as per the International Agency for Research on Cancer (IARC) guidelines.17 The KKCR has a completeness rating of 97.0%.18

The sources of information for the cancer registry include databases from regional and community hospitals, pathology departments, and death certificates. The lag-time between diagnosis and reporting is less than 1 year, and only 3.2% of cases are based upon information from a death certificate only (DCO cases). All cases are encoded as per the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3).19

Case definitions

The database was searched for all patients with CCA tumors living in Khon Kaen Province between January 1, 1989 and December 31, 2013. CCA is an ICD-O-3 diagnosis, and only the cases with coding C22.1, C24.0, C24.8, and C24.9 (excluding C24.1, Ampulla of Vater) were included.20 Patients diagnosed from 1985 through 1988 were excluded because, at that time, registries were only just opening and the data lacked completeness, making the ASR unreliable.

Statistical methods

Percentages were used to describe proportions of the categorical data. The mean (standard deviation [SD]) was used to describe the continuous variables. Incidence trends were assessed using the estimated annual percentage change (APC) of the world ASRs. The Jointpoint regression program (version 4.0.4; The Surveillance, Epidemiology, and End Results [SEER] program of the National Cancer Institute [NCI], Rockville, MD, USA.)21 was used to investigate the trends in the incidence rate of CCA, identify points where a significant change in the linear slope of the trends occurred, and the corresponding P-value and 95% confidence interval (CI) of the APC. We then determined the incidences of CCA in Khon Kaen Province from 1989 through 2013 and projected future trends from 2014 through 2030.22 A maximum of one point was allowed in each regression. A value of 0.01 was added to all of the years in the data series for the dependent variable where a zero value was observed in 1 or more years. To determine survival, we calculated the follow-up time from diagnosis to the last known vital status of each patient; this was obtained by linking records between the Mortality Registry of Thailand23 and the National Statistical Office16 (updated to December 31, 2016). Focusing on stage of disease and period of time, the survival analysis was estimated using the Kaplan-Meier survival curve, and the log-rank test was used for between group comparisons.24 Since the mean age at diagnosis of the neoplasms is high and other medical conditions may have influenced patient death, we also analyzed observed survival (OS) by stage of disease and period of diagnosis. In addition, we illustrated relative survival (RS), the ratio between observed survival (OS) and expected survival.25 RS was analyzed and adapted from the Hakulinen method.26,27 RS was estimated using the mortality tables for Khon Kaen Province. The results for RS were corrected for mortality by causes other than cancer, especially in older populations.

All statistical tests were two-sided with a significance level of 0.05. No adjustment of the alpha level was made for multiple testing. All statistical analyses were implemented using the Stata release 10 (StataCorp LLC, College Station, TX, USA).28

Data processing

Data were recorded using CanReg 5 software provided by the IARC (International Agency for Research on Cancer, Lyon, France).29 The verification was performed with necessary correction, including logic, range, and internal consistency, which were checked using Stata 10.0 Statistical Software (Stata Corp)28 and Epidata Software (The EpiData Association, Denmark).30

Ethical considerations

The present study was approved by the Institutional Review Board (HE581074), under the Office of Human Research Ethics, Khon Kaen University.

RESULTS

Descriptive epidemiology

We identified 11,711 cases of CCA in the KKCR database for the period 1989 through 2013. The male to female ratio was 2.2:1. The mean age was 62.6 (SD, 11.2) years. The age at diagnosis trended to be high. The other variables did not vary significantly. The most common stage of disease was ‘unknown staging’ (76.2%; n = 8,927) and “late stage” (ie, Stage III and IV; 23.3%; n = 2,722). Histological grading was commonly missing from the data (97.5%; n = 11,414) (Table 1). The primary bases of diagnosis were endoscopic and radiologic evidence versus morphological verification (10.6%; n = 1,247) (ie, based on either cytological or histological examination of tissue from the primary site, %MV) (data not shown).

Table 1. Characteristics of study participants at recruitment by 5-year periods.

Characteristic 1989–1993 1994–1998 1999–2003 2004–2008 2009–2013





n % n % n % n % n %
1. Sex
 Males 1,295 69.7 1,356 70.9 1,925 68.05 1,838 68.2 1,598 66.2
 Females 564 30.3 557 29.1 904 31.95 857 31.8 817 33.8
Male to female ratio; 2.2:1 1.3:1 2.4:1 2.1:1 2.1:1 2.1:1
2. Age at diagnosis, year of age
 30–40 104 5.6 75 4.0 94 3.3 62 2.3 34 1.4
 41–50 300 16.2 291 15.3 344 12.2 281 10.5 172 7.1
 51–60 630 33.9 611 31.9 754 26.7 737 27.4 532 22.0
 61–98 825 44.3 936 48.8 1,637 57.8 1,615 59.8 1,677 69.5
 Mean (SD) = 62.6 (11.2) 59.0 (10.9) 60.2 (10.8) 62.1 (10.9) 63.1 (10.8) 65.7 (10.6)
 Median (Min: Max) = 63 (30:98) 59.0 (30:92) 60.0 (30:94) 63.0 (30:97) 64.0 (30:96) 66.0 (30:98)
3. Stage at diagnosis
 Stage I 5 0.3 1 4 0.2
 Stage II 2 0.1 14 0.5 14 0.6
 Stage III 3 0.2 2 0.1 15 0.6 41 1.7
 Stage IV 446 24.0 394 20.6 560 19.8 654 24.5 607 25.1
 Unknown 1,410 75.8 1,512 79.0 2,267 80.1 1,989 74.4 1,749 72.4
4. Histological grading
 Well-differentiated 11 0.6 61 2.2 54 2.0 52 2.2
 Moderately-differentiated 1 0.1 21 0.7 22 0.8 24 1.0
 Poorly-differentiated 1 0.1 20 0.7 14 0.5 12 0.5
 Undifferentiated 1 2 0.1 1
 Unknown 1,858 100.0 1,901 100.0 2,726 96.4 2,603 96.5 2,326 96.3

Incidence

Age-standardized incidence rates (ASR)

The respective ASR rate per 100,000 for CCA for (a) males, (b) females, and (c) males and females from 1989 through 2013 ranged from (a) 25.2 to 58.8, (b) 9.9 to 23.6, and (c) 17.5 to 39.9 (Figure 1). Thus, the overall ASR per 100,000 was 41.5 for males (95% CI, 40.6–42.4), 16.6 for females (95% CI, 16.1–17.1), and 28.1 for males and females (95% CI, 27.6–28.7) (Figure 1).

Figure 1. Incidence rates (per 100,000 per year) for CCA by sex in Khon Kaen Province from 1989 through 2013.

Figure 1.

The ASR for CCA for all age groups, both males and females, for the whole period (1989 through 2013) has significantly decreased over time. The exception was for patients between 61 and 98 years, for whom the ASR initially increased in the first three periods but decreased in the last two (Table 2).

Table 2. Incidence by time period, age group, and sex in Khon Kaen Province from 1989 through 2013.
Characteristic Period of time Males Females Both sexes




Age group, years n CR ASR 95% CI n CR ASR 95% CI n CR ASR 95% CI
30–40 1989–1993 53 1.23 1.1 0.77 to 1.34 25 0.61 0.5 0.30 to 0.69 78 0.96 0.77 0.6 to 0.95
1994–1998 39 0.93 0.7 0.48 to 0.92 13 0.31 0.2 0.10 to 0.35 52 0.62 0.5 0.33 to 0.85
1999–2003 52 1.22 0.9 0.64 to 1.12 17 0.39 0.3 0.15 to 0.41 69 0.80 0.6 0.44 to 0.71
2004–2008 32 0.76 0.6 0.38 to 0.78 13 0.30 0.2 0.10 to 0.34 45 0.53 0.4 0.28 to 0.51
2009–2013 21 0.50 0.4 0.24 to 0.60 5 0.11 0.1 0.01 to 0.18 26 0.30 0.3 0.15 to 0.35
41–50 1989–1993 191 4.4 5.2 4.44 to 5.92 82 2.0 2.2 1.72 to 2.68 273 3.67 3.7 3.23 to 4.11
1994–1998 198 4.73 4.7 4.07 to 5.39 64 1.52 1.5 1.12 to 1.85 262 3.12 3.1 2.71 to 3.76
1999–2003 212 4.96 4.3 3.74 to 4.91 87 2.01 1.8 1.40 to 2.15 299 3.47 3.0 2.68 to 3.37
2004–2008 184 4.38 3.5 2.95 to 3.95 59 1.35 1.1 0.79 to 1.33 243 2.84 2.2 1.94 to 2.50
2009–2013 111 2.66 1.9 1.58 to 2.31 40 0.93 0.6 0.44 to 0.83 151 1.97 1.4 1.22 to 1.65
51–60 1989–1993 429 12.52 16.1 14.73 to 17.45 163 3.98 4.5 3.85 to 5.24 592 7.26 8.6 7.87 to 9.25
1994–1998 410 13.02 14.0 12.83 to 15.18 163 3.87 4.0 3.36 to 4.57 573 6.82 7.2 6.59 to 7.77
1999–2003 519 12.14 11.5 10.47 to 12.44 200 4.61 4.2 3.61 to 4.76 719 6.65 6.2 5.65 to 6.66
2004–2008 495 11.79 9.20 8.36 to 9.98 196 4.49 3.4 2.93 to 3.88 691 8.07 6.19 5.73 to 6.66
2009–2013 331 7.92 5.2 4.66 to 5.79 146 3.28 2.1 1.78 to 2.47 477 5.53 3.6 3.29 to 3.94
61–98 1989–1993 614 14.23 23.4 21.4 to 25.34 293 7.16 11.1 9.84 to 12.40 907 11.13 18.5 17.32 to 19.74
1994–1998 705 16.85 26.3 24.37 to 28.25 315 7.47 9.8 8.71 to 10.88 1020 12.4 17.3 16.25 to 18.37
1999–2003 1136 21.61 28.5 26.62 to 30.28 598 13.78 14.9 13.70 to 16.09 1734 11.84 14.1 13.28 to 15.02
2004–2008 1125 26.79 27.2 25.57 to 28.74 587 13.44 11.5 10.55 to 12.42 1712 19.99 18.5 17.67 to 19.43
2009–2013 1134 27.13 21.3 20.9 to 22.58 626 14.08 9.4 8.69 to 10.19 1760 20.40 14.8 14.1 to 15.50

ASR, age-standardize rate; CI, confidence interval; CR, crude rate.

Focusing on all ages, for the period 1989 through 2013, the Joinpoint regression revealed that the incidence was significantly decreasing by: (a) −2.0% per year among males (average annual percent change [AAPC] −2.0; 95% CI, −3.4 to −0.6); (b) −1.5% per year among females (AAPC −1.5; 95% CI, −3.1 to 0.1); and, (c) −1.9% per year among males and females (AAPC −1.9%; 95% CI, −3.3 to −0.5). Accoding to the Joinpoint analysis of years, the incidence rate among males increased with an APC of 1.7% (95% CI, −0.3 to 3.7) from 1989 through 2002, and decreased with an APC of 6.2% (95% CI, −8.4 to −4.0). By comparison, among females the incidence rate increased with an APC of 2.2% (95% CI, −0.2 to 4.6) from 1989 through 2002, and decresed with an APC of 5.7% (95% CI, −8.1 to −3.1) (Figure 2a and Figure 2b). The simulated projection curve of CCA incidence from 2014 through 2030 indicates that rates are expected to continue to decrease to 17.5 per 100,000 in males. Females are expected to reach 7.7 per 100,000, while both sexes are predicted to reach 12.2 per 100,000. The incidence will be stable over the next 10 years but will still exceed the average worldwide incidence (Figure 2c).

Figure 2. Joinpoint trends for age-adjusted rates per 100,000 for CCA in Khon Kaen Province from 1989–2002 and 2002–2013. a) Males; b) Females, and c) Simulated CCA incidence trend projections to 2030. ASR, age standardized rate.

Figure 2.

Lastly, for boths males and females, the incidence rate increased 1.8% (95% CI, −0.2 to 3.8) from 1989 through 2002, and decreased with an APC of 6.1% (95% CI, −8.2 to −3.9) (Table 3).

Table 3. Number of cases and annual percentage of change in incidence rate of CCA in Khon Kean Province from 1989 through 2013.
Characteristic Period of time Males Females Both sexes




All ages n APC 95% CI, P-value n APC 95% CI, P-value n APC 95% CI, P-value
  1989–2002 4,156 1.70 (−0.3 to 3.7), 0.100 1,823 2.19 (−0.2 to 4.6), 0.100 5,979 1.79 (−0.2 to 3.8), 0.100
  2002–2013 3,856 −6.24 (−8.4 to −4.0), <0.001 1,876 −5.71 (−8.1 to −3.2), <0.001 5,732 −6.09 (−8.2 to −3.9), <0.001

APC, annual percentage change; CI, confidence interval.

Figure 3 illustrates the incidence of CCA was declining parallel with the prevalence of O. viverrini. The data from the national and local level reveal a decreasing proportion of infection, which is consistent with the ASR for CCA in Thailand.

Figure 3. Age-adjusted rates per 100,000 (both sexes, ASR), OV (%)-Thailand, and OV (%)-KK in Khon Kaen Province trend downward. ASR, age standardized rate; KK, Khon Kaen Province; OV, Opisthorchis viverrini.

Figure 3.

Survival

The respective OS versus RS at 1, 3, and 5 years for the different age groups of CCA is presented in Table 4. At 5 years, the respective OS and RS for males aged 30–40, 41–50, 51–60, and 61–98 years of age was 23.2% (95% CI, 17.0 to 30.4%) versus 23.4% (95% CI, 17.1 to 31.6%), 12.6% (95% CI, 10.1 to 15.7%) versus 13.1% (95% CI, 10.5 to 16.2%), 7.4% (95% CI, 6.0 to 9.0%) versus 7.7% (95% CI, 6.2 to 9.2%), and 6.8% (95% CI, 5.9 to 7.8%) versus 6.9% (95% CI, 6.0 to 7.9%). For females, the respective OS versus RS for age groups of 30–40, 41–50, 51–60, and 61–98 years of age was 19.0% (95% CI, 10.2 to 35.4%) versus 19.2% (95% CI, 10.3 to 35.7%), 16.7% (95% CI, 12.3 to 22.5%) versus 17.5% (95% CI, 13.2 to 23.4%), 11.1% (95% CI, 8.7 to 14.1%) versus 11.2% (95% CI, 8.8 to 14.2%), and 7.6% (95% CI, 6.4 to 9.1%) versus 7.7% (95% CI, 6.4 to 9.2%) (Table 4).

Table 4. Overall observed survival and relative survival of CCA for each age-group and sex in Khon Kaen Province from 1989 through 2013.

Characteristic Survival time Males Females Both sexes




Age groups, years n OS (95% CI) RS (95% CI) n OS (95% CI) RS (95% CI) n OS (95% CI) RS (95% CI)
30–40 1 year 49 35.5 (28.5 to 44.1) 36.3 (29.3 to 45.1) 19 38.7 (27.6 to 54.3) 41.0 (29.6 to 56.6) 68 37.0 (30.9 to 44.3) 37.7 (31.5 to 45.0)
3 years 28 25.2 (18.8 to 33.6) 26.4 (19.9 to 34.9) 11 24.9 (15.2 to 40.8) 25.1 (15.3 to 41.2) 39 25.1 (20.2 to 33.7) 26.1 (20.4 to 33.3)
5 years 23 23.2 (17.0 to 30.4) 23.4 (17.2 to 31.6) 7 19.0 (10.2 to 35.4) 19.2 (10.3 to 35.7) 25 22 (16.6 to 29.2) 22.3 (16.8 to 29.5)
41–50 1 year 141 24.8 (21.6 to 28.4) 25.1 (21.9 to 28.7) 61 26.6 (21.5 to 32.9) 27.6 (22.4 to 34.0) 202 25.5 (22.8 to 28.6) 25.7 (23.0 to 28.8)
3 years 68 13.8 (11.3 to 17.0) 13.9 (11.4 to 17.1) 37 18.0 (13.6 to 23.8) 18.1 (13.7 to 24.0) 105 14.9 (12.6 to 17.7) 15.1 (12.8 to 17.8)
5 years 40 12.6 (10.1 to 15.7) 13.1 (10.5 to 16.2) 23 16.7 (12.3 to 22.5) 17.5 (13.2 to 23.4) 63 13.7 (11.4 to 16.4) 14.3 (12.0 to 17.0)
51–60 1 year 284 19.3 (17.4 to 21.3) 19.4 (17.6 to 21.5) 135 23.1 (20.0 to 26.6) 23.3 (20.2 to 26.8) 419 20.4 (18.8 to 22.2) 20.5 (18.9 to 22.3)
3 years 108 9.2 (7.9 to 10.9) 9.4 (8.0 to 11.0) 62 13.3 (10.8 to 16.4) 13.6 (11.1 to 16.7) 170 10.4 (9.1 to 11.8) 10.6 (9.3 to 12.0)
5 years 46 7.4 (6.0 to 9.0) 7.6 (6.2 to 9.2) 40 11.1 (8.7 to 14.1) 11.2 (8.8 to 14.2) 86 8.5 (7.3 to 9.9) 8.6 (7.8 to 10.0)
61–98 1 year 534 16.8 (15.6 to 18.1) 16.8 (15.6 to 18.1) 329 19.4 (17.7 to 21.3) 19.5 (17.7 to 21.4) 863 17.7 (16.7 to 18.7) 17.7 (16.7 to 18.8)
3 years 227 8.6 (7.7 to 9.7) 8.7 (7.8 to 9.8) 125 9.8 (8.4 to 11.3) 9.9 (8.5 to 11.5) 352 9.1 (8.3 to 9.9) 9.1 (8.3 to 10.0)
5 years 114 6.8 (5.9 to 7.8) 6.9 (6.0 to 7.9) 64 7.6 (6.4 to 9.1) 7.7 (6.4 to 9.2) 174 7.1 (6.4 to 7.9) 7.2 (6.4 to 8.0)

CI, confidence interval; OS, overall survival; RS, relative survival.

Focusing on stage of disease and period of time, the results of the log-rank test showed significant relationships between patient survival and stage of disease and period of time (P-value <0.001) (Figure 4 and Figure 5).

Figure 4. Kaplan-Meier survival curves for patients with CCA in Khon Kaen Province from 1989 through 2013. The curves represent the TMN stage.

Figure 4.

Figure 5. Kaplan-Meier survival curves for males (a) and females (b) with CCA in Khon Kaen Province from 1989 through 2013. The curves represents periods of time. CI, confidence interval.

Figure 5.

DISCUSSION

The current study showed that the incidence of CCA has been significantly decreasing by (a) −2.0% per year among males, (b) −1.50% per year among females, and (c) −1.9 per year among males and females. This is consistent with the reported incidence in our previous study and the ASR of liver and bile duct cancer as reported by the Thailand Cancer Registry. The most common histological type was CCA.29

We have hypothesized that the decline in the incidence of CCA in our previous study may be the real falling risk.15 The updated decline in incidence confirms our hypothesis. The decrease in the incidence of CCA might be the result of controlling the risk factors associated with O. viverrini infection. The incidence of O. viverrini infection has been decreasing over time, from >60% in 1984 to <10% after 1997.31 The declining incidence parallels a decline in O. viverrini infection rates over the last 20 years.

Several studies have addressed the unique risk factors of CCA in some countries.32 Since O. viverrini infection is believed to be one of the risk factors of cholangiocarcinogenesis in Thailand,33 a process that takes decades, time was also needed to evaluate the effectiveness of O. viverrini infection control (Figure 3). Numerous government policies aimed at decreasing the rate of O. viverrini infection, including: (a) liver fluke control units, established in 1967; (b) continuous health education, also established in 1967; (c) a liver fluke control program, embedded in the 5-year National Public Health Development Plan (1987–1991)34; and (d) the Promotion of Community Health through Parasitic Control in seven northeastern provinces, in cooperation with the Federal Republic of Germany government, run from 1989–1992. The liver fluke control program continues to be an element of the National Public Health Developmant Plan.14,31

Our data show that, while the elderly continue to eat raw fish, the younger generations are avoiding eating it. The results indicate that O. viverrini infection occurred predominantly in the elderly over younger age groups.35 Education appears to be more effective in the young than the elderly. The life cycle of O. viverrini and risk factors for CCA should thus be introduced in primary school.

We found that the predicted incidence of CCA will be stable over the next 10 years, albeit higher than in other parts of the world,36 suggesting that there are unidentified risk factors other than O. viverrini infection and nitrosamine. With respect to the latter factor, in other research, we attempted to demonstrate that repeated use of praziquantel could increase the risk of CCA, but the evidence was weak.37 Further research is needed to identify other risk factors for CCA, particularly other environmental factors that could be controlled (ie, pesticides and carcinogens in the food chain).

The survival of CCA patients remains poor, despite improvements in diagnostic technology and surgical techniques. Several reasons may account for this finding: (a) most patients in northeastern Thailand present for care at a late stage of CCA, when only palliative treatment is an option38; (b) stringent criteria for resection means that some patients are denied surgery; and (c) after 2006, a new classification of bile duct tumors (ie, intraductal papillary neoplasm of the bile duct [IPNB]) was introduced, which was previously included with CCA. Since the prognosis of IPNB is relatively good, the survival of CCA before 2006 appeared to have been better than after IPNB was no longer included as a CCA.39,40

Conclusion

The incidence of CCA in Khon Kaen Province has been decreasing over the last 10–12 years, coinciding with government efforts to control risk factors related to O. viverrini infection. The projected incidence of CCA should remain stable over the next 10 years, although it is higher than the worldwide incidence. The survival of CCA patients remains poor, so it is important to identify other risk factors, apart from O. viverrini and nitrosamine, that could be targeted to lower the incidence, as well as employing a screening program to detect eartlier stage that might improve survival.

ACKNOWLEDGEMENTS

We thank (a) Khon Kaen University (KKU) for financial support, (b) the KKU Cancer Unit staff for data collection and management, and (c) Mr. Bryan Roderick Hamman for assistance with the English-language presentation of the manuscript under the aegis of the Publication Clinic, Research Affairs, KKU.

Conflicts of interest: None declared.

REFERENCES

  • 1.Ferlay J, Soerjomataram I, Ervik M, et al. Cancer Incidence and Mortality Worldwide. Lyon, Frence: IARC CancerBase No. 11 [Internet]; [cited 2016 Sep 27]. Available from: http://globocan.iarc.fr.
  • 2.Vatanasapt V, Martin N, Sriplung H, et al. Cancer in Thailand Vol. I, 1988–1991. Bangkok: IARC Technical Report No. 16, Lyon, IARC; 1993.
  • 3.Deerasamee S, Martin N, Sontipong S, et al. Cancer in Thailand Vol. II, 1992–1994. Bangkok: IARC Technical Report No. 34, Lyon: IARC; 1999.
  • 4.Sriplung H, Sontipong S, Martin N, et al. Cancer in Thailand Vol. III, 1995–1997. Bangkok: Bangkok Medical Publisher; 2003. [Google Scholar]
  • 5.Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P. Cancer in Thailand Vol. IV, 1998–2000. Bangkok: Bangkok Medical Publisher; 2007. [Google Scholar]
  • 6.Khuhaprema T, Srivatanakul P, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y. Cancer in Thailand Vol. V, 2001–2003. Bangkok: Bangkok Medical Publisher; 2010. [Google Scholar]
  • 7.Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y, Sangrajrang S. Cancer in Thailand Vol. VI, 2004–2006. Bangkok: Bangkok Medical Publisher; 2012. [Google Scholar]
  • 8.Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sangrajrang S. Cancer in Thailand Vol. VII, 2007–2009. Bangkok: Bangkok Medical Publisher; 2013. [Google Scholar]
  • 9.Imsamran W, Chaiwerawattana A, Wiangnon S, et al. Cancer in Thailand Vol. VIII, 2010–2012. Bangkok: Bangkok Medical Publisher; 2015. [Google Scholar]
  • 10.Bhamarapravati N, Virranuvatti V. Liver diseases in Thailand. An analysis of liver biopsies. Am J Gastroenterol. 1966;45:267–275. [PubMed] [Google Scholar]
  • 11.Thamavit W, Moore MA, Ruchirawat S, Ito N. Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic Praziquantel lacks carcinogenic potential. Carcinogenesis. 1992;13:309–311. 10.1093/carcin/13.2.309 [DOI] [PubMed] [Google Scholar]
  • 12.Sripa B, Yongvanit P, Pairojkul C. Etiology and pathogenesis of cholangiocarcinoma: introduction to the association with liver fluke infection. Srinagarind Med J. 2005;20:122–134. [Google Scholar]
  • 13.Sithithaworn P. Current roles of liver fluke on occurrence of cholangiocarcinoma. Srinagarind Med J. 2005;20:135–142. [Google Scholar]
  • 14.Jongsuksuntigul P, Imsomboon T. Opisthorchiasis control in Thailand. Acta Trop. 2003;88:229–232. 10.1016/j.actatropica.2003.01.002 [DOI] [PubMed] [Google Scholar]
  • 15.Kamsa-ard S, Wiangnon S, Suwanrungruang K, et al. Trends in liver cancer incidence between 1985 and 2009, Khon Kaen, Thailand: cholangiocarcinoma. Asian Pac J Cancer Prev. 2011;12:2209–2213. [PubMed] [Google Scholar]
  • 16.Nation Statistical Office [Internet]. [cited 2017 Mar 7]. Available from: http://www.nso.go.th/.
  • 17.Esteban D, Whelan S, Laudico A, Parkin DM. Manual for Cancer Registry Personnel [Internet]. [cited 2018 Mar 12]. Available from: http://publications.iarc.fr/Book-And-Report-Series/Iarc-Technical-Publications/Manual-For-Cancer-Registry-Personnel-1995.
  • 18.Suwanrungruang K, Sriplung H, Attasara P, et al. Quality of case ascertainment in cancer registries: a proposal for a virtual three-source capture-recapture technique. Asian Pac J Cancer Prev. 2011;12:173–178. [PubMed] [Google Scholar]
  • 19.WHO | International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) [Internet]. WHO. [cited 2017 Mar 7]. Available from: http://www.who.int/classifications/icd/adaptations/oncology/en/.
  • 20.Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology (ICD-O) – 3rd edition, 1st revision. [Internet]. World Health Organization; [cited 2016 Oct 18]. Available from: www.who.int.
  • 21.National Cancer Institute. Jointpoint Regression Program-Surveillance Research Program [Internet]. Jointpoint Regression Program-Surveillance Research Program. [cited 2017 Mar 7]. Available from: https://surveillance.cancer.gov/joinpoint/.
  • 22.Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–351. [DOI] [PubMed] [Google Scholar]
  • 23.National Health Office (NHSO), Thailand [Internet]. [cited 2017 Mar 7]. Available from: http://www.nhso.go.th/eng/Site/Default.aspx.
  • 24.Survival Analysis - A Self-Learning Text, Third Edition | David G. Kleinbaum | Springer [Internet]. [cited 2017 Apr 18]. Available from: http://www.springer.com/gp/book/9781441966452.
  • 25.Estève J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990;9:529–538. 10.1002/sim.4780090506 [DOI] [PubMed] [Google Scholar]
  • 26.Hakulinen T, Seppä K, Lambert PC. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011;47:2202–2210. 10.1016/j.ejca.2011.03.011 [DOI] [PubMed] [Google Scholar]
  • 27.Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101–121. [PubMed] [Google Scholar]
  • 28.Stata: Data Analysis and Statistical Software [Internet]. 2012 [cited 2012 Dec 8]. Available from: http://www.stata.com/.
  • 29.IACR - CanReg5 [Internet]. [cited 2017 Apr 3]. Available from: http://www.iacr.com.fr/index.php?option=com_content&view=article&id=9:canreg5&catid=68&Itemid=445.
  • 30.EpiData Software - http://www.epidata.dk [Internet]. [cited 2017 Mar 7]. Available from: http://www.epidata.dk/.
  • 31.Jongsuksuntigul P, Imsomboon T. Epidemiology of opisthorchiasis and national control program in Thailand. Southeast Asian J Trop Med Public Health. 1998;29:327–332. [PubMed] [Google Scholar]
  • 32.Sobue T, Utada M, Makiuchi T, et al. Risk of bile duct cancer among printing workers exposed to 1,2-dichloropropane and/or dichloromethane. J Occup Health. 2015;57:230–236. 10.1539/joh.14-0116-OA [DOI] [PubMed] [Google Scholar]
  • 33.Kamsa-ard S, Kamsa-ard S, Luvira V, Suwanrungruang K, Vatanasapt P, Wiangnon S. Risk factors for cholangiocarcinoma in Thailand: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2018;19:605–614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bureau of Health Promotion. Development and primary health care within the 6th National Economic and Social Development Plan (1987–1991). Bangkok (Published in Thai); 1987. [Google Scholar]
  • 35.Upatham ES, Viyanant V, Kurathong S, et al. Relationship between prevalence and intensity of Opisthorchis viverrini infection, and clinical symptoms and signs in a rural community in north-east Thailand. Bull World Health Organ. 1984;62:451–461. [PMC free article] [PubMed] [Google Scholar]
  • 36.Globocan 2012. International Agency for Research on Cancer, WHO. http://globocan.iarc.fr/Default.aspx; 2016. Accessed 12.06.17.
  • 37.Kamsa-Ard S, Luvira V, Pugkhem A, et al. Association between praziquantel treatment and cholangiocarcinoma: a hospital-based matched case-control study. BMC Cancer. 2015;15:776. 10.1186/s12885-015-1788-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Luvira V, Nilprapha K, Bhudhisawasdi V, Pugkhem A, Chamadol N, Kamsa-ard S. Cholangiocarcinoma patient outcome in northeastern Thailand: single-center prospective study. Asian Pac J Cancer Prev. 2016;17:401–406. 10.7314/APJCP.2016.17.1.401 [DOI] [PubMed] [Google Scholar]
  • 39.Luvira V, Somsap K, Pugkhem A, et al. Morphological classification of intraductal papillary neoplasm of the bile duct with survival correlation. Asian Pac J Cancer Prev. 2017;18:207–213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Luvira V, Pugkhem A, Bhudhisawasdi V, et al. Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct. J Gastroenterol Hepatol. 2017;32:527–533. 10.1111/jgh.13481 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology are provided here courtesy of Japan Epidemiological Association

RESOURCES